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Abstract
Background: In patients with type 2 diabetes, the risk for cardiovascular disease is substantial. To achieve a more
favourable risk profile, lifestyle changes on diet, physical activity and smoking status are needed. This will involve
changes in behaviour, which is difficult to achieve. Cognitive behavioural therapies focussing on self-management
have been shown to be effective. We have developed an intervention combining techniques of Motivational
Interviewing (MI) and Problem Solving Treatment (PST). The aim of our study is to investigate if adding a
combined behavioural intervention to managed care, is effective in achieving changes in lifestyle and cardiovascular
risk profile.
Methods: Patients with type 2 diabetes will be selected from general practices (n = 13), who are participating in
a managed diabetes care system. Patients will be randomised into an intervention group receiving cognitive
behaviour therapy (CBT) in addition to managed care, and a control group that will receive managed care only.
The CBT consists of three to six individual sessions of 30 minutes to increase the patient's motivation, by using
principles of MI, and ability to change their lifestyle, by using PST. The first session will start with a risk assessment
of diabetes complications that will be used to focus the intervention.
The primary outcome measure is the difference between intervention and control group in change in
cardiovascular risk score. For this purpose blood pressure, HbA1c, total and HDL-cholesterol and smoking status
will be assessed. Secondary outcome measures are quality of life, patient satisfaction, physical activity, eating
behaviour, smoking status, depression and determinants of behaviour change. Differences between changes in the
two groups will be analysed according to the intention-to-treat principle, with 95% confidence intervals. The
power calculation is based on the risk for cardiovascular disease and we calculated that 97 patients should be
included in every group.
Discussion: Cognitive behavioural therapy may improve self-management and thus strengthen managed diabetes
care. This should result in changes in lifestyle and cardiovascular risk profile. In addition, we also expect an
improvement of quality of life and patient satisfaction.
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Background
Diabetes mellitus is a major health problem. It was esti-
mated that in 2000 approximately 177 million people
worldwide had diabetes, and this number is expected to
double by the year 2030 [1]. Cardiovascular disease is the
leading cause of death among patients with diabetes. Both
cardiovascular disease and diabetes are associated with
similar risk factors, namely unhealthy diet, smoking and a
sedentary lifestyle. These factors contribute to a severely
elevated morbidity and mortality of patients with diabetes
[2-5]. In the last few years it has been shown that interven-
tions can lower these risk factors and improve cardiovas-
cular and microvascular endpoints [6-10].
In previous studies it has been shown that different behav-
ioural interventions are effective in changing lifestyle of
patients with diabetes [11-14]. However, it is not entirely
clear what kind of therapy is most effective [15]. We
believe that a combined behavioural intervention, con-
sisting of a motivational phase and problem solving tech-
niques that is tailored to lifestyle determinants has to be
used [11-14]. To our knowledge, this has not yet been
studied.
The aim of our study is to evaluate if adding a combined
behavioural intervention to managed diabetes care, is
effective in improving the cardiovascular risk profile of
patients with type 2 diabetes.
Diabetes Care System (DCS)
In addition to the care of the GPs and their practice nurses,
in West-Friesland, the Netherlands, an extensive diabetes
management programme, is implemented [16]. In short,
each patient visits annually the diabetes research center
for a physical examination. In addition, the patient visits
a diabetes nurse and a dietician for information and
advice and is invited for follow-up visits when necessary.
The results of this annual examination are sent to the
patient's GP, who is responsible for the management of
the patient and delegation of tasks to their practice nurse,
according to the guidelines of the Dutch College of Gen-
eral Practitioners. These guidelines recommend every
patient with diabetes to visit a GP every 3 months [17,18].
At present, 3800 patients, representing 80% of all type 2
diabetes patients in the sub-region West-Friesland are
enrolled in this Diabetes Care System (DCS). The mean
HbA1c of these patients was 7.0% in 2005. However,
according to current guidelines of the Dutch College of
General Practitioners [18] more than 60% of the patients
participating in the DCS still had a HbA1c ≥ 7.0% and 90%
of the patients had a HbA1c ≥ 8.5%. In addition, 20% of
the patients still smoked, 80% was overweight and 70%
had little or no physical activity. These findings show that
the DCS was successful in controlling hyperglycaemia, but
failed with respect to the lifestyle factors. Our findings are
similar to those of other diabetes management programs
[19]. This implies that there is a need for innovative pro-
grammes to improve the quality of care for diabetes
patients, with a specific focus on lifestyle factors.
Cognitive behavioural therapy (CBT)
During the last few decades, several models have been
developed to explain and predict health behaviour. A
common used model is the Atittude, Social influence, and
self-Efficacy model (ASE-model) [20-22]. It mainly incor-
porates the attitudes and social influences determinants of
the Theory of Reasoned Action and the self-efficacy con-
cept of Bandura's Social Cognitive Theory [23]. This
model has proven to be effective for developing behav-
ioural interventions in different research areas and will be
used in our study to evaluate if the determinants of behav-
iour of the patient have changed after the CBT [24-26].
The ASE-model assumes that behaviour has three primary
determinants: attitudes, social influences and self-efficacy.
Together, they determine the intention of a person to per-
form a specific behaviour. In this model, a person's atti-
tude towards a specific behaviour is determined by its
perceived affective (evaluative) and cognitive conse-
quences. The social influences are determined by social
norms, perceptions of the behaviour of others and per-
ceived social support or pressure for execution of the
behaviour. The self-efficacy expectations can be seen as a
person's belief in his or hers ability to perform the desired
behaviour in specific social, emotional and habitual situ-
ations. These three determinants are not entirely inde-
pendent of each other; they can all be seen as cognitions
that the person has regarding the importance of execution
of a specific behaviour.
We developed a CBT that consists of two parts: Motiva-
tional Interviewing and Problem Solving Treatment.
Motivational Interviewing (MI)
MI is a client-oriented, directive method for enhancing
intrinsic motivation to change by exploring and resolving
ambivalence [27]. The four guiding principles of MI are:
express empathy, develop discrepancies, roll with resist-
ance and support self-efficacy.
Expressing empathy involves providing clients with an
atmosphere of respect and acceptance of their position.
The technique used is reflective listening and this is gener-
ally considered the foundation of MI and is recom-
mended throughout the whole counselling process.
The second principle of MI involves creating a 'gap'
between the client's current behaviour and their broader
goals, thus cultivating motivation for lifestyle change.BMC Public Health 2007, 7:74 http://www.biomedcentral.com/1471-2458/7/74
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When the client recognizes such discrepancies, a certain
level of discontent arises that makes change more likely to
occur. Discrepancies are developed by exploring the cli-
ent's important life values and reviewing how their cur-
rent behaviours affect their ideal lifestyle.
The third principle, rolling with resistance, is based on the
idea that directly challenging resistance is counterproduc-
tive to lifestyle change, because it typically results in the
client defending the current state of affairs. Rather, resist-
ance should be rolled with and channelled instead of con-
fronted. Rolling with resistance invites the client to
consider a new perspective versus having it imposed.
Finally, self-efficacy, or one's confidence in the ability to
change a specific behaviour under difficult circumstances,
should be supported whenever possible because it is one
of the best predictors of treatment outcome. Self-efficacy
can be strengthened by affirming past success (i.e., rein-
forcement), presenting success stories of others (i.e., mod-
elling), and expressing belief in the client's potential to
change.
Together, these four principles guide the first phase of
CBT. The patient will become motivated and at that point,
the Problem Solving Treatment can be started.
Problem Solving Treatment (PST)
PST is a practical skill building treatment and might there-
fore be effective in achieving lifestyle changes in patients
with diabetes [28].
PST was originally described by D'Zurilla and Godfried
[29] and later expanded and refined by D'Zurilla and
Nezu [30]. PST may be defined as the self-directed cogni-
tive-behavioural process by which a person attempts to
identify effective or adaptive solutions for specific prob-
lems encountered in everyday living [31]. The effects of
PST have been shown to be effective in patients with
depression [32-34]. However, PST is potentially useful in
the treatment of any disorder in which a patient is experi-
encing multiple daily problems and stresses and is not
coping effectively with them [31]. Therefore, patients with
diabetes might benefit from PST as they have to cope with
many complex tasks. They have to take care of their diet,
lifestyle, physical activity and administration of oral med-
ication or insulin in order to achieve an optimal glycaemic
control and to reduce their cardiovascular risk factors.
Also, psychological problems are common in these
patients. PST might increase the patients' ability to solve
their problems in a structured way and their confidence in
facing future problems and therefore improve their diabe-
tes self-management.
PST can be considered as a series of stages [28]:
1. Explanation of the intervention and its rationale
2. Definition and breaking down of the problem
3. Establishing achievable goals for problem resolution.
Achievable goals are SMART goals: Specific, Measurable,
Achievable, Relevant, Timed
4. Generating multiple possible solutions
5. Evaluating and choosing the solution
6. Implementing the preferred solution
7. Evaluating the outcome
Another reason why PST may be suitable in patients with
diabetes is that practice nurses can deliver it because it is
relatively brief, as it lasts between three and six sessions of
30 minutes [32,35].
Objectives
The primary objective of our study is to investigate if cog-
nitive behavioural therapy, when added to managed dia-
betes care, is effective in achieving changes in
cardiovascular risk profile. The secondary objective is to
assess whether the cognitive behavioural therapy is effec-
tive in changing lifestyle.
Methods
Design of the study
The study is a randomised controlled trial (RCT). The
Medical Ethical Committee of the VU University Medical
Center in Amsterdam approved the study design, proto-
cols, information letters to the patients and informed con-
sent form.
Setting
The trial is conducted within 'the Diabetes Care System
(DCS)', a managed care system that was implemented in
The Netherlands, as described above. This care system has
a well organised infrastructure with experienced medical
assistants, diabetes nurses and dieticians and is therefore
a suitable setting to implement a new therapy for patients
with diabetes.
Study population
The source population consist of patients with type 2 dia-
betes of participating GPs. Selection criteria for the GPs
are that they have a practice nurse and that they are part of
the DCS. GPs will be informed about the study by one of
the researchers (GN) and a diabetes nurse and are asked
to participate. They have to sign an intention declaration
to confirm participation.BMC Public Health 2007, 7:74 http://www.biomedcentral.com/1471-2458/7/74
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Patients from the participating GPs, who are scheduled to
visit the DCS for their annual visit, are sent an informa-
tion letter on the study. This letter is announced in the tel-
ephone call that the reception of the DCS has with the
patient to make an appointment for their annual visit at
the medical assistant.
Patients visit the medical assistant for their annual physi-
cal examination of the DCS. The medical assistant checks
eligibility of the patient for the study. Patients are eligible
if they meet the following inclusion criteria: diagnosis of
type 2 diabetes, between 40 and 75 years of age, able to
understand the Dutch language in order to understand the
study protocol, written informed consent and question-
naires, high risk for cardiovascular disease and diabetic
complications. Patients are considered at risk if, according
to measurements of the previous annual visit, HbA1c ≥ 7.0
% and/or body mass index ≥ 27.0 kg/m2  and/or the
patient smokes. In addition, all newly diagnosed patients,
who do not have annual check-up results available, are
considered eligible, based on the fact that all new patients
need to learn how to deal with their diabetes. If all inclu-
sion criteria are met, the medical assistant explains the
purpose of the study and patients are asked if they are
interested in participation.
All patients must sign a written informed consent form.
Subsequently, physical measurements are performed,
which include body weight, waist circumference, blood
pressure, and drawing of blood samples (to assess fasting
blood glucose, HbA1c, total cholesterol, HDL-cholesterol
and triglycerides). In addition, patients are given a self-
administrated questionnaire to fill in at home, including
questionnaires on physical activity, dietary intake, smok-
ing status, determinants of behaviour according to the
ASE-model, quality of life, depression, general health and
patient satisfaction. The responsible GP is informed that
the patient is participating in the study. During the study,
GPs receive fax forms from the diabetes nurses and dieti-
cians advising on required medication changes for a spe-
cific patient.
Treatment allocation
Patients are randomly assigned to either the intervention
group, receiving CBT in addition to the managed diabetes
care or the control group, receiving managed diabetes care
only. Approximately three weeks after the visit to the med-
ical assistant, patients are scheduled for either the first
intervention or control session to the diabetes nurse and
dietician.
Block randomisation is performed within the general
practices in order to eliminate the influence of different
treatments of general practitioners. From each general
practice, half of the patients are randomised to the inter-
vention group or the control group. The principle investi-
gator (LMCW), who is not involved in the selection and
treatment of patients, prepared a randomisation list using
series of random numbers [36]. Random permuted blocks
of 4 patients are made to ensure equal distribution of
patients for each general practice. The manager of the
DCS, who is not involved in the patients' care, allocates
the patient to one of the two groups by using the randomi-
sation list. The flow of the patients is registered by the
principal investigator (LMCW), according to a flow dia-
gram recommended by the CONSORT statement [37].
Reasons for withdrawal are registered by the medical
assistant. Figure 1 shows the design of the study.
Blinding
Patients, diabetes nurses and dieticians cannot be blinded
to the intervention. The medical assistants are blinded as
far as possible. They have close contact with the diabetes
nurses and dieticians within the DCS and therefore we
cannot guarantee the blinding of the medical assistants.
However, they are not involved in the intervention.
The principal investigator, the GPs and their practices
nurses remain blinded during the entire intervention. This
is achieved by giving instructions to the patients prefera-
bly not to communicate about the intervention with their
GPs and practice nurses. To evaluate the success of blind-
ing, GPs will be asked to fill in a questionnaire to investi-
gate to which group each of their participating patients
they believed were allocated.
Interventions
Control group
Patients allocated to the control group receive managed
diabetes care provided by the DCS.
This managed diabetes care consists of three elements.
Firstly, these patients are invited by means of a telephone
call from the reception of the DCS to make an appoint-
ment for an annual physical examination at the medical
assistant. Secondly, the patient visits a diabetes nurse and
dietician, for 30 minutes each, in order to receive general
information and advice on diabetes problems, dietary
intake and physical activity. The results of the physical
examination and the recommendations of the diabetes
nurses and dietician are sent to the patients' GP, in order
to stimulate the GP to follow the guidelines of the Dutch
College of General Practitioners [17,18]. Thirdly, the DCS
coordinates the care of the patient between the general
practices and secondary diabetes care.
Patients in the control group are scheduled for one visit to
the diabetes nurse and for one visit to the dietician; fol-
low-up visits are optional.BMC Public Health 2007, 7:74 http://www.biomedcentral.com/1471-2458/7/74
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Design of the RCT Figure 1
Design of the RCT.
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Intervention group
Patients who are assigned to the intervention group
receive CBT in addition to the same managed care. The
CBT is performed by diabetes nurses and dieticians, who
received a training of two days in the performing of CBT
prior to the onset of the study. Additionally, two instruc-
tion days on the implementation of the intervention were
arranged. A treatment manual is used during the study to
guide the treatment. All CBT sessions are tape-recorded to
assess treatment fidelity of the diabetes nurse or dietician
to the protocol. In addition, these tape-recordings are
used in supervision sessions to provide ongoing feedback.
Each diabetes nurse and dietician haves supervision once
every four weeks with a psychologist (PvO) who is special-
ised in CBT. This psychologist is also available by email or
telephone between the supervision sessions.
A pilot study was performed before the start of the study
to provide three practice sessions for each diabetic nurse
and dietician and to assess logistic pathways of the study.
There were 10 caregivers involved in the study, which
means that 30 patients were included in the pilot study. A
supervision meeting was scheduled after the pilot study to
discuss logistic pathways and skills to perform the CBT of
every caregiver.
The CBT starts with a visit to the diabetes nurse. Results of
the baseline measurements can be used to motivate the
patient to change. With the help of MI techniques, a prob-
lem list is created by the patient focused on lifestyle
(smoking behaviour, diet and physical activity). When the
most important problem is related to smoking or physical
activity, the patient visits the diabetes nurse during the
next sessions. When the most important problem is
related to diet, the patient is rescheduled to visit the dieti-
cian during follow-up sessions. From that moment, the
patient remains with the same diabetes nurse or dietician
during the entire study.
After the MI phase, is it time to strengthen commitment to
a lifestyle change plan. At this point, the patient is willing
and able to change. Signs of this readiness for change are:
decreased resistance, decreased discussion about the prob-
lem, reaching some kind of resolution, increasing change
talks, questions about the change, and envisioning how
life might be after a change. At this time, the diabetes
nurse or dietician makes, together with the patient, an
implementation plan where, when and how the behav-
iour changes will be performed. The formulation of this
plan makes it easier for patients to carry out intended
actions. This will be done by PST [28-31].
The CBT consists of three to six visits of 30 minutes to the
diabetes nurses or dieticians at the DCS. There is a focus
on one problem area in each session. During all sessions,
both the MI and the PST skills are used to motivate the
patients, set new goals and review the patients' progress.
The last CBT session is brought to an end by reviewing and
emphasising the entire CBT process, with emphasis on
achieved successes of the patient and implementation of
CBT in the future, independently of the diabetes nurse or
dietician. The GPs provide ongoing feedback during the
intervention.
Co-interventions and compliance
Co-interventions are avoided during the intervention by
means of the fact that the control group was scheduled to
a diabetes nurse that did not receive the training on CBT.
In addition, all caregivers in the Diabetes Care System
have access to the same central database which includes
clinical characteristics of the patients and details on given
advice and information. This centralisation avoids co-
interventions. However, any co-intervention is reported.
Compliance to the CBT is assessed by registration of the
number of sessions that patients attend.
Compliance to the intervention is considered adequate
when at least three sessions are attended. For the patients
in the control group, the number of follow-up visits to the
diabetes nurse or dietician is also registered. The number
of visits to the GPs or hospital is registered for both the
intervention and the control group.
Outcome assessment
Outcome measurements are assessed at baseline, and
again after 6 and 12 months by means of self-reported
questionnaires and physical examinations at the DCS.
Physical examinations are performed by medical assist-
ants of the DCS. These included weight, height, waist cir-
cumference, blood pressure, fasting blood glucose,
HbA1c, triglycerides (at baseline and 12 months only),
total cholesterol (at baseline and 12 months only) and
HDL-cholesterol (at baseline and 12 months only).
Demographic variables on age, gender, diabetes duration,
marital status, ethnicity, level of education and eventual
occupation are assessed at baseline by using a self-admin-
istered questionnaire, which also includes all secondary
outcomes. The medical assistants ask the patients infor-
mation on medication (the patient brings the packages of
medication to the visit), hospital admission days and
number of general practitioner visits. Patients are
informed of their measurements by the diabetes nurse
and dietician. Measurements are also send to their GPs.
Primary outcome measures
The primary outcome measure is the difference between
intervention and control group in change in cardiovascu-
lar risk score after 12 months. The cardiovascular risk
score is based on the Oxford Risk Engine (algorithm that
includes: age at diagnosis, duration of diabetes, sex, eth-BMC Public Health 2007, 7:74 http://www.biomedcentral.com/1471-2458/7/74
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nicity, smoking status, systolic blood pressure, HbA1c,
total cholesterol, HDL-cholesterol) [38].
Secondary outcomes measures
Secondary outcomes measures are included in a self-
reported questionnaire that is filled in by the patients at
home. Patients will be sent a questionnaire at baseline,
after 6 and 12 months. All the secondary outcomes are
included in the questionnaire, with the exception of the
Patients' evaluation of the Quality of Diabetes Care Ques-
tionnaire (PEQD), which is not assessed at baseline.
1. Diet is assessed by the use of the Dutch Eating Behav-
iour Questionnaire (DEBQ). This is a 33-item question-
naire regarding diet behaviour, scored on a five point scale
(1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = very
often). This questionnaire assess whether a patient is a
restraint, emotional or external eater [39].
2. Short Questionnaire to Assess Health Enhancing Phys-
ical Activity (SQUASH) is used to assess physical activity.
This questionnaire consists of subscales concerning (A)
commuting activities, (B) leisure time activities, (C)
household activities, and (D) activities at work and school
[40].
3. Smoking: Smoking is assessed by asking patients if they
are a never smoker, current smoker or past smoker.
4. ASE-questionnaire: a 20-item questionnaire, created by
the investigators themselves according to the ASE-model:
Attitude, Social influences and self-Efficacy model [41].
To our knowledge, no validated questionnaires were
available. The theoretical model and questionnaires of
other running studies at their own research institute were
used to develop the ASE-questionnaire. Each item is pro-
vided with a 7-point Likert-type scale describing only the
two end points.
5. Quality of life is measured by the EuroQol. This ques-
tionnaire consists of 5 dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depres-
sion), each with 3 levels, and a visual analogue scale on
which patients rate their own health between 0 and 100
[42,43].
6. Depression during the last week is assessed by the use
of the CES-D: Center for Epidemiological Studies Depres-
sion scale. This is a 20-item questionnaire with a four-
point scale (1 = seldom or never, 2 = sometimes, 3 = often,
4 = mostly or always) [44].
7. The Patient Health Questionnaire (PHQ9) is used to
assess the general health of the patient. This brief PHQ
consists of 9 items, measured on a four-point scale (1 =
not at all, 2 = several days, 3 = more than half of the days,
4 = almost every day) in order to assess depressive disor-
ders during the last two weeks [45].
8. The patient satisfaction on the diabetes care provided
by medical assistants, diabetes nurses and dieticians is
measured by the use of the Patients' evaluation of the
Quality of Diabetes Care Questionnaire (PEQD). For each
health care provider, 14 items are evaluated on a five-
point scale, ranging from "poor" to "excellent" [46].
Physical measurements
Physical measurements are performed to calculate the car-
diovascular risk score and to describe the patients' charac-
teristics.
1. Anthropometric measurements. Body weight and
height are measured for the calculation of the Body Mass
Index (weight divided by height squared). Waist circum-
ference is measured at the level midway between the low-
est rib margin and the iliac crest.
2. Systolic and diastolic blood pressure is measured after
5 minutes of rest in seated position by Collin Press Mate
(BP-8800, Komaki-City).
3. Blood samples are taken in order to determine:
• fasting plasma glucose: measured in plasma by means of
a hexokinase-method (Roche Diagnostics GmbH, Man-
nheim, Germany).
￿ HbA1c: measured by High Performance Liquid Chroma-
tography
￿ Total cholesterol, HDL-cholesterol and triglycerides by
means of enzymatic techniques (Boehringer-Mannheim,
Mannheim, Germany).
4. In addition, data are collected from the patients on:
￿ hospital admission days per 6 months
￿ number of visits to general practitioner per 6 months
￿ medication changes per 6 months
Sample size
The sample size is calculated on the base of the minimally
clinically relevant difference in changes of one of the pri-
mary outcome measurements, the Oxford Risk Engine
[38]. In the DCS the standard deviation of the absolute
risk for cardiovascular disease, calculated with the Oxford
Risk Engine, was 10%. A difference (d) between the inter-
vention and control group in changes of 5% absolute riskBMC Public Health 2007, 7:74 http://www.biomedcentral.com/1471-2458/7/74
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(about the same as can be expected by giving a cholesterol
lowering agent, i.e. a statin as medication), a standard
deviation (sd) of 10%, an alpha of 0.05 (two-sided), and
a power of 90% leads to 68 participants in each group. A
multilevel analysis was performed to calculate the correla-
tion of the outcome measures within practices. A correla-
tion (r) of 20% was found and for that reason the number
of participants has to be multiplied with a factor 0.8 (1 –
correlation, to adjust for the block randomisation within
general practices), leading to 68 patients (n) in each
group. The formula used was [47,48]:
n1 = n2 = 2(Z1-α/2 + Z1-β)2 sd2 (1-r)/d2
Z1-α/2 = Z (1 - 0.05/2) = Z 0.975 = 1.96
Z1-β = Z 0.90 = 1.282
sd = 0.10, r = 0.20, d = 0.05
n1 = n2 = 2 * (1.96 + 1.282)2 * (sd*sd)* (1-r)/(d*d) =
2 * 10.51 * (0.1 * 0.1) * (1 - 0.2)/(0.05 * 0.05) = 68
patients. Taking into account a possible drop-out rate of
30% the number of participants to be randomised must
be 194 (97 in each group).
Analyses
Comparability between the two groups will be assessed at
baseline. On the basis of an intention-to-treat analysis,
differences in changes between the intervention and the
control group are measured with 95% confidence inter-
vals at 12 months for both primary and secondary out-
comes. For dichotomous outcome variables a multilevel
logistic regression analysis will be used. To calculate dif-
ferences between continuous variables a multilevel analy-
sis will be used, to adjust for the clustering of observations
of patients receiving care from the same GP, and for
repeated measurements within one patient. We will also
perform a per-protocol analysis with patients that have
attended at least three CBT sessions.
We will adjust data for possible confounders: age, gender,
weight at start of study, diabetes duration, level of educa-
tion, depression, smoking, number of attended sessions,
general practitioner, and type of health care provider (dia-
betes nurse or dietician).
Discussion
This article provides a detailed description of the study
design of an RCT on the added value of cognitive behav-
ioural therapy focused on changing lifestyle in patients
with type 2 diabetes and is published with two purposes.
Firstly, to provide the opportunity for other researchers,
health care providers and policy makers to critically
review the methodological quality, the background theory
and the practical issues of the RCT. Secondly, the publica-
tion of this study design prevents publication bias. Studies
with non-significant results are less likely to get published
than studies with significant results. For that reason, the
result of meta-analyses will be biased. The publication of
our study design before the results become available will
therefore prevent publication bias. The study becomes
identifiable in search strategies for a systematic review
and/or meta-analysis [49]. In addition, the authors bear
more responsibility to publish the results, irrespective of
the results appear to be positive or negative.
We expect that the addition of a cognitive behavioural
therapy to managed diabetes care will be effective in
changing lifestyle in patients with type 2 diabetes. As a
result of that, we expect that a changed lifestyle will cause
a risk reduction in cardiovascular disease. The implemen-
tation of such a study into an existing managed diabetes
care system is unique. This system provides experienced
medical assistants, diabetes nurses and dieticians and a
high-quality infrastructure for patients with diabetes. One
could argue, that, because the setting is well organised, the
results of this trial cannot be easily generalised to all
patients with diabetes. However, when the results appear
to be negative, it is very unlikely that such an intervention
will have success in a general setting.
There are some limitations in the study design. We expect
that patients who agree to participate are more motivated
to change than patients who refuse to participate. How-
ever, because the design of the study is a randomised con-
trolled trial, this will be the case in both groups. Having a
population of motivated patients might decrease the
drop-out percentage. Patients in the control group may
improve their lifestyle behaviour just by the knowledge
that their outcomes are being used for research. However,
this may also occur in the intervention group. Patients in
the intervention group may benefit from the attention
they get. However, because it is possible that patients in
the control group receive follow-up visits as well, we can
identify sub-groups based on number of sessions and
compare the outcomes of the intervention and the control
sub-groups in order to make a distinction between the
effect of attention and the intervention.
Another limitation of this study is the lack of a validated
questionnaire for an important primary outcome meas-
ure, the ASE-questionnaire. This questionnaire is sepa-
rated into three dimensions (diet, physical activity and
smoking). Because the use of validated questionnaires to
assess the amount of physical activity, the diet behaviour
and the amount of smoking, we can compare these out-
comes with the ASE-questionnaire. We expected that these
correlate with each other. It might therefore be possible toBMC Public Health 2007, 7:74 http://www.biomedcentral.com/1471-2458/7/74
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validate the ASE-questionnaire in this study. This might
not only increase the quality of this study but can also pro-
vide a questionnaire for other researchers.
The study already started at the end of 2005. The inclusion
of patients will take one year, till the end of 2006. The
one-year follow-up period of all patients is finished at the
end of 2007 and results will then become available. If this
study appears to have positive effects, the behavioural
intervention might also be implemented in other care set-
tings.
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